Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806650 · ClinicalTrials.gov registry record
Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 155
- Enrollment target
NCT00806650 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 155 participants.
The verdict
NCT00806650 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 155 participants
- Enrollment target
Study Summary
This research trial studies the development of a blood test for detecting anti-insulin-like growth factor II mRNA binding protein 3 (anti-IMP3) antibody and micro ribonucleic acid (microRNA) in patients with renal cell carcinoma (RCC) that has spread to other parts of the body (metastatic) or is limited to the tissue or organ where it began (localized). Anti-IMP3 is a tumor marker that can be detected in many human cancers, including RCC and is likely to be present in the serum (blood) of patients with metastatic or localized RCC. Alterations in microRNA expression has also shown to play a critical role in cancer progression and may be a promising biomarker for patients with RCC. Developing a blood test for anti-IMP3 antibody and microRNA in serum and tissue samples of patients in the laboratory may help doctors find and diagnose RCC earlier, find out how far the disease has spread, and plan effective treatment for RCC.
Interventions
- GENETIC gene expression analysis
- GENETIC protein expression analysis
- OTHER immunohistochemistry staining method
- OTHER immunoenzyme technique
- DIAGNOSTIC_TEST diagnostic laboratory biomarker analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2008-07 |
| Est. Completion | 2017-11-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806650
The ClinicalTrials.gov registry entry for NCT00806650 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which gene expression analysis is the first listed.
NCT00806650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806650 about?
NCT00806650 is a clinical study titled "Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer". This research trial studies the development of a blood test for detecting anti-insulin-like growth factor II mRNA binding protein 3 (anti-IMP3) antibody and micro ribonucleic acid (microRNA) in patients with renal cell carcinoma (RCC) that has spread to other parts of the body (metastatic) or is lim...
What is the current status of trial NCT00806650?
This trial is currently completed. The enrollment target is 155 participants. The study started on 2008-07. Estimated completion is 2017-11-15.
What interventions are being tested in trial NCT00806650?
The interventions under investigation include: gene expression analysis (GENETIC), protein expression analysis (GENETIC), immunohistochemistry staining method (OTHER), immunoenzyme technique (OTHER), diagnostic laboratory biomarker analysis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00806650?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.